Alembic receives USFDA final approval for Prazosin Hydrochloride Capsules
Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure
Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure
Fluorouracil Injection is indicated for the treatment of patients with adenocarcinoma of colon and rectum and breast
USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
Pregabalin Capsules have an estimated market size of US $244 million for twelve months ending Sep 2022 according to IQVIA
Desonide Cream, 0.05%, has an estimated market size of US $12 million for twelve months ending Sep 2022 according to IQVIA
This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA
Subscribe To Our Newsletter & Stay Updated